Profile data is unavailable for this security.

About the company

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

  • Revenue in CHF (TTM)59.20bn
  • Net income in CHF11.78bn
  • Incorporated1966
  • Employees94.44k
  • Location
    Roche Holding AGGrenzacherstr. 124BASEL 4058SwitzerlandCHE
  • Phone+41 9 732354295
  • Websitehttp://www.roche.com
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
ROG:VTX since
Promedior IncAnnounced15 Nov 201915 Nov 2019Announced2.23%1.39bn
Data delayed at least 15 minutes, as of Dec 13 2019 16:30 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Takeda Pharmaceutical Co Ltd25.88bn140.72m62.77bn49.58k137.871.4212.632.4332.1032.102,130.243,123.560.33541.864.6458,025,380.000.18431.360.21551.7765.2269.830.54943.830.93820.47140.5078226.3318.454.39-41.610.458611.300.00
Bayer AG47.99bn-1.64bn76.34bn104.71k--1.4419.481.59-1.53-1.3044.6949.290.33571.733.74374,852.60-1.144.12-1.395.2857.4258.83-3.398.160.88264.110.486969.6713.05-0.286-47.83-11.873.756.26
Novartis AG48.77bn7.10bn230.26bn109.00k29.863.9918.264.723.054.9920.9522.820.38292.216.04389,649.605.576.817.138.4170.9066.5514.5517.420.728357.900.364174.616.050.170265.026.53-0.13660.9933
Roche Holding Ltd.59.20bn11.78bn258.84bn94.44k22.029.1716.064.3713.6513.6968.6832.780.74772.455.33626,882.1015.4312.8223.0319.0571.2171.1520.6418.761.1032.820.386975.826.653.9719.61-1.2818.772.21
Data as of Dec 13 2019. Currency figures normalised to Roche Holding AG's reporting currency: Swiss Franc CHF

Institutional shareholders

15.12%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Oct 201920.70m2.95%
Norges Bank Investment Managementas of 31 Dec 201818.48m2.63%
Fidelity Management & Research Co.as of 31 Oct 201913.01m1.85%
UBS Asset Management Switzerland AGas of 04 Dec 201911.49m1.64%
BlackRock Fund Advisorsas of 05 Dec 201910.29m1.47%
Z�rcher Kantonalbank (Investment Management)as of 31 Oct 20197.44m1.06%
Massachusetts Financial Services Co.as of 31 Oct 20196.95m0.99%
Credit Suisse Asset Management (Schweiz) AGas of 29 Nov 20196.34m0.90%
FIL Investment Advisors (UK) Ltd.as of 31 Oct 20195.91m0.84%
Dodge & Coxas of 30 Sep 20195.62m0.80%
More ▼
Data from 31 Dec 2018 - 10 Dec 2019Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.